Company facts
- Headquarters
- New York, New York
- Most recent report
- 8-K, filed Sep 22, 2026
- Filings on record
- 357 filings
- On EDGAR
- CIK 1907108
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 8 of 13
News 8 of 37
Prospectuses and Registrations 8 of 37
- S-8 Registration statement for an employee plan Mar 30, 2026
- 424B3 Prospectus supplement for an offering Nov 26, 2025
- S-3 Shelf registration statement Nov 5, 2025
- S-8 Registration statement for an employee plan Nov 5, 2025
- 424B5 Prospectus supplement for an offering Oct 17, 2025
- FWP Free writing prospectus Oct 17, 2025
- 424B5 Prospectus supplement for an offering Oct 16, 2025
- FWP Free writing prospectus Oct 16, 2025
Proxies 7
- DEFA14A Extra proxy material Apr 30, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 30, 2026
- DEFA14A Extra proxy material Jun 5, 2025
- DEFA14A Extra proxy material Apr 28, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 28, 2025
- DEFA14A Extra proxy material Apr 26, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 26, 2024
Ownership 8 of 224
- 4 Insider reported a trade Sep 28, 2026
- 4 Insider reported a trade Sep 28, 2026
- 4 Insider reported a trade Sep 28, 2026
- 4 Insider reported a trade Sep 28, 2026
- 4 Insider reported a trade Aug 19, 2026
- 4 Insider reported a trade Aug 19, 2026
- 4 Insider reported a trade Aug 19, 2026
- 144 Notice of a proposed sale of restricted stock Aug 18, 2026
Other 8 of 39
- ARS Annual report sent to shareholders Apr 30, 2026
- EFFECT Notice that a registration became effective Nov 26, 2025
- CORRESP Reply to SEC staff Nov 25, 2025
- EFFECT Notice that a registration became effective Jun 30, 2025
- CORRESP Reply to SEC staff Jun 27, 2025
- CORRESP Reply to SEC staff Jun 26, 2025
- UPLOAD Comment letter from SEC staff Jun 18, 2025
- ARS Annual report sent to shareholders Apr 28, 2025
Everything here comes from Lexeo Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.